Delfi Diagnostics’ cfDNA-based FirstLook Lung assay increased lung cancer screening uptake in a cluster-randomized FIRSTLUNG trial, the company reported at the ATS International Conference. Among nearly 3,000 patients behind on screening across Colorado, Florida, and North Carolina, the test showed 80% sensitivity, 56% specificity, and 99.8% negative predictive value. The study also found a nearly three-fold increase in overall screening rates and a 1.5-fold increase in low-dose CT screening after patients gained access to the blood test. Delfi said many of the cancers detected were stage I and the company has submitted the results for peer-reviewed publication.